Botulinum Toxin or Sacral Neuromodulation for Refractory OAB: Her Hands Decide More Than the Trial Did
Two third-line therapies with comparable efficacy in the largest trial that's ever compared them — until a detail in her own hands makes one of their harms far more costly to her than the trial's average patient.
Dolores M., 66, spent thirty years as a seamstress in a garment alterations shop before her rheumatoid arthritis forced her to retire four years ago, and now volunteers folding donated clothing at her church's outreach program a few mornings a week — work she can still manage, unlike the fine needlework that used to be her livelihood. Her RA has been present for eighteen years, currently managed on methotrexate and a biologic with reasonable disease control, but has left her with visible ulnar deviation and reduced grip strength in both hands, formally documented on a recent occupational therapy assessment as moderately impaired fine motor dexterity.
Her overactive bladder has been refractory for over two years: she has failed adequate trials of both an antimuscarinic (twelve weeks of solifenacin) and a beta-3 agonist (sixteen weeks of mirabegron), each discontinued for insufficient benefit rather than intolerance, placing her squarely at the third-line decision point per AUA/SUFU guidance — onabotulinumtoxinA injection or sacral neuromodulation. ROSETTA, the largest randomized trial to compare these two options head to head, gave botulinum toxin a small six-month edge its own investigators called of uncertain clinical importance (-3.9 versus -3.3 daily episodes), and by two years the two arms were indistinguishable — a genuinely reassuring efficacy result either way. The same two-year follow-up complicates a purely efficacy-driven choice, though: women treated with botulinum toxin reported higher satisfaction but had recurrent urinary tract infections at 24% against 10% for sacral neuromodulation, with 6% needing intermittent catheterization after a second injection — a task her own hands may not reliably be able to perform. Her documented moderate impairment is not a small deviation from ROSETTA's average participant on that one variable; it is the variable the trial never measured. Her post-void residual today measured 40mL, comfortably normal, so nothing about catheterization is a live problem this morning. She is being asked to choose today, on a normal number, whether to accept a treatment whose characteristic harm would land on the one function eighteen years of rheumatoid arthritis have already taken from her.
A trial's average harms against her own hands
I'd start with onabotulinumtoxinA. ROSETTA compared it directly against sacral neuromodulation in exactly her situation — refractory urgency incontinence after failed drug therapy — and if anything favored it slightly at six months, with the two arms level by twenty-four. It's also reversible and office-based, sparing her a permanent implanted device and everything that comes with it: lead migration, device infection, eventual battery replacement surgery.
Efficacy parity is only half of what ROSETTA measured. The trial's own two-year follow-up put recurrent urinary tract infections at 24% after botulinum toxin against 10% after sacral neuromodulation, with 6% of the toxin arm needing clean intermittent catheterization after a second injection. That's a real, accumulating cost across repeat injection cycles, not a one-time consideration — this isn't a single decision, it's a treatment course she may be on for years.
Both of you are debating a harm that assumes she can perform intermittent self-catheterization if it becomes necessary. I'm not confident that assumption holds. Her occupational therapy assessment already documents moderately impaired fine motor dexterity from eighteen years of rheumatoid arthritis — the ulnar deviation and reduced grip strength in her hands are the same reason she gave up needlework four years ago.
If catheterization becomes necessary and she genuinely can't manage it reliably, that isn't a quality-of-life inconvenience the way it might be for a dexterous patient — it's a real access problem that could mean urinary retention going unmanaged.
Agreed: proceed to sacral neuromodulation staged trial, with hand-function testing revisited explicitly if botulinum toxin is ever reconsidered later in her care.
Not agreed: the urogynecologist maintains that a formal, direct test of her catheterization ability — rather than inferring it from the OT dexterity assessment alone — should have been tried before ruling out botulinum toxin entirely, since some patients with hand impairment adapt with catheter-holder devices the assessment didn't account for; the urologist and primary care physician considered the OT documentation sufficient grounds to proceed directly to the option without the catheterization dependency.